Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death

Carcinogenesis

Volumn 36, Issue , 2015, Pages S89-S110

  Narayanan, Kannan Badri ^a   Ali, Manaf ^b   Barclay, Barry J ^c   Cheng, Qiang ^d   D'Abronzo, Leandro ^e   Dornetshuber Fleiss, Rita ^f   Ghosh, Paramita M ^e   Gonzalez Guzman, Michael J ^g   Lee, Tae Jin ^h   Leung, Po Sing ⁱ   Li, Lin ⁱ   Luanpitpong, Suidjit ^j   Ratovitski, Edward ^k   Rojanasakul, Yon ^l   Romano, Maria Fiammetta ^m   Romano, Simona ^m   Sinha, Ranjeet Kumar ⁿ   Yedjou, Clement ^o   Al Mulla, Fahd ^p   Al Temaimi, Rabeah ^p   Amedei, Amedeo ^q   Brown, Dustin G ^r   Ryan, Elizabeth P ^r   Colacci, Annamaria ^s   Hamid, Roslida A ^t   Mondello, Chiara ^u   Raju, Jayadev ^v   Salem, Hosni K ^w   Woodrick, Jordan ^x   Scovassi, Ivana ^q   Singh, Neetu ^y   Vaccari, Monica ^s   Roy, Rabindra ^x   Forte, Stefano ^z   Memeo, Lorenzo ^z   Kim, Seo Yun ^aa   Bisson, William H ^ab   Lowe, Leroy ^ac   Park, Hyun Ho ^a   more..

^a Yeungnam University   (South Korea)

^b UNIVERSITI SULTAN ZAINAL ABIDIN   (Malaysia)

^c Plant Biotechnologies Inc   (Canada)

^d Southern Illinois University at Carbondale   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^h Yeungnam University College of Medicine   (South Korea)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j MAHIDOL UNIVERSITY   (Thailand)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l WEST VIRGINIA UNIVERSITY   (United States)

^m UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁿ SCRIPPS RESEARCH INSTITUTE   (United States)

^o Jackson State University   (United States)

^p KUWAIT UNIVERSITY   (Kuwait)

^q UNIVERSITY OF FLORENCE   (Italy)

^r Veterinary Dentistry and Oral Surgery   (United States)

^s Center for Environmental Carcinogenesis and Risk Assessment   (Italy)

^t UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^u CNR   (Italy)

^v TOXICOLOGY RESEARCH DIVISION   (Canada)

^w CAIRO UNIVERSITY   (Egypt)

^x GEORGETOWN UNIVERSITY   (United States)

^y KING GEORGE'S MEDICAL UNIVERSITY   (India)

^z Mediterranean Institute of Oncology   (Italy)

^aa Korea Cancer Center Hospital   (South Korea)

^ab OREGON STATE UNIVERSITY   (United States)

^ac Getting to Know Cancer   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BH3 PROTEIN; CASPASE; CHLOROTHALONIL; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH RECEPTOR; DICHLORVOS; ENVIRONMENTAL CHEMICAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAP JUNCTION PROTEIN; LINDANE; LINURON; METHOXYCHLOR; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHTHALIC ACID DIBUTYL ESTER; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; CARCINOGEN; DANGEROUS GOODS;

APOPTOSIS; AUTOPHAGY; CANCER GROWTH; CANCER RISK; CELL COMMUNICATION; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CHEMICAL CARCINOGENESIS; CYTOPLASM; DNA DAMAGE; DNA FRAGMENTATION; GAP JUNCTION; GENE MUTATION; GONADOTROPIN SECRETING CELL; HUMAN; HYPOPHYSIS; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NECROPTOSIS; NEOPLASM; NONHUMAN; ONCOGENE; POLLUTANT; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; ADVERSE EFFECTS; ANIMAL; CARCINOGENESIS; CHEMICALLY INDUCED; DANGEROUS GOODS; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; HOMEOSTASIS; NEOPLASMS;

ANIMALS; CARCINOGENESIS; CARCINOGENS, ENVIRONMENTAL; CELL DEATH; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HOMEOSTASIS; HUMANS; NEOPLASMS;

EID: 84937698903     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv032     Document Type: Review

References (353)

1. Nicholson, D.W. et al. (2003) Apoptosis. Life and death decisions. Science, 299, 214-215.
2. Fridman, J.S. et al. (2003) Control of apoptosis by p53. Oncogene, 22, 9030-9040.
3. Shortt, J. et al. (2012) Oncogenes in cell survival and cell death. Cold Spring Harb. Perspect. Biol., 4.
4. Orr, B. et al. (2013) A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front. Oncol., 3, 164.
5. Croce, C.M. (2008) Oncogenes and cancer. N. Engl. J. Med., 358, 502-511.
6. Hetz, C.A. et al. (2005) Beyond apoptosis: nonapoptotic cell death in physiology and disease. Biochem. Cell Biol., 83, 579-588.
7. de Bruin, E.C. et al. (2008) Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev., 34, 737-749.
8. Elmore, S. (2007) Apoptosis: a review of programmed cell death. Toxicol. Pathol., 35, 495-516.
9. Falschlehner, C. et al. (2007) TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol., 39, 1462-1475.
10. Suh, D.H. et al. (2013) Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front. Oncol., 3, 41.
11. Mayer, B. et al. (2003) Mitochondrial regulation of apoptosis. News Physiol. Sci., 18, 89-94.
12. Adams, J.M. (2003) Ways of dying: multiple pathways to apoptosis. Genes Dev., 17, 2481-2495.
13. Keinan, N. et al. (2010) Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis. Mol. Cell. Biol., 30, 5698-5709.
14. Vander Heiden, M.G. et al. (2001) Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane. J. Biol. Chem., 276, 19414-19419.
15. Broker, L.E. et al. (2005) Cell death independent of caspases: a review. Clin. Cancer Res., 11, 3155-3162.
16. Vermeulen, K. et al. (2005) Apoptosis: mechanisms and relevance in cancer. Ann. Hematol., 84, 627-639.
17. Yang, Y.L. et al. (2000) The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res., 10, 169-177.
18. Carew, J.S. et al. (2002) Mitochondrial defects in cancer. Mol. Cancer, 1, 9.
19. Park, H.H. et al. (2007) Death domain assembly mechanism revealed by crystal structure of the oligomeric PIDDosome core complex. Cell, 128, 533-546.
20. Kim, I.R. et al. (2009) DNA damage- and stress-induced apoptosis occurs independently of PIDD. Apoptosis, 14, 1039-1049.
21. Park, H.H. (2011) Structural analyses of death domains and their interactions. Apoptosis, 16, 209-220.
22. Van Cruchten, S. et al. (2002) Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol., 31, 214-223.
23. Jaattela, M. et al. (2003) Caspase-independent cell death in T lymphocytes. Nat. Immunol., 4, 416-423.
24. Chautan, M. et al. (1999) Interdigital cell death can occur through a necrotic and caspase-independent pathway. Curr. Biol., 9, 967-970.
25. Galluzzi, L. et al. (2008) Necroptosis: a specialized pathway of programmed necrosis. Cell, 135, 1161-1163.
26. Kaczmarek, A. et al. (2013) Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity, 38, 209-223.
27. Mehrpour, M. et al. (2010) Autophagy in health and disease. 1. Regulation and significance of autophagy: an overview. Am. J. Physiol. Cell Physiol., 298, C776-C785.
28. Degenhardt, K. et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell, 10, 51-64.
29. Glick, D. et al. (2010) Autophagy: cellular and molecular mechanisms. J. Pathol., 221, 3-12.
30. He, C. et al. (2009) Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet., 43, 67-93.
31. Karantza-Wadsworth, V. et al. (2007) Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev., 21, 1621-1635.
32. Mathew, R. et al. (2007) Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev., 21, 1367-1381.
33. Mathew, R. et al. (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell, 137, 1062-1075.
34. Aita, V.M. et al. (1999) Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics, 59, 59-65.
35. Qu, X. et al. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest., 112, 1809-1820.
36. Hu, Y.L. et al. (2012) Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res., 72, 4294-4299.
37. Fesik, S.W. (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer, 5, 876-885.
38. Lowe, S.W. et al. (2000) Apoptosis in cancer. Carcinogenesis, 21, 485-495.
39. Plati, J. et al. (2011) Apoptotic cell signaling in cancer progression and therapy. Integr. Biol. (Camb)., 3, 279-296.
40. Dewey, W.C. et al. (1995) Radiation-induced apoptosis: relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 33, 781-796.
41. Bal, W. et al. (2002) Induction of oxidative DNA damage by carcinogenic metals. Toxicol. Lett., 127, 55-62.
42. Johnstone, R.W. et al. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108, 153-164.
43. Stenner-Liewen, F. et al. (2003) Apoptosis and cancer: basic mechanisms and therapeutic opportunities in the postgenomic era. Cancer Res., 63.
44. Dalerba, P. et al. (2007) Cancer stem cells: models and concepts. Annu. Rev. Med., 58, 267-284.
45. Levina, V. et al. (2008) Drug-selected human lung cancer stem cells:cytokine network, tumorigenic and metastatic properties. PLoS One, 3, e3077.
46. D'Andrea, F.P. (2012) Intrinsic radiation resistance of mesenchymal cancer stem cells and implications for treatment response in a murine sarcoma model. Dan. Med. J., 59, B4388.
47. Kruyt, F.A. et al. (2010) Apoptosis and cancer stem cells: implications for apoptosis targeted therapy. Biochem. Pharmacol., 80, 423-430.
48. Frisch, S.M. et al. (2013) Mechanisms that link the oncogenic epithelialmesenchymal transition to suppression of anoikis. J. Cell Sci., 126(Pt 1), 21-29.
49. Liu, G. et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 5, 67.
50. Zobalova, R. et al. (2008) CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem. Biophys. Res. Commun., 373, 567-571.
51. Ouyang, L. et al. (2012) Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif., 45, 487-498.
52. Strasser, A. et al. (2011) Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J., 30, 3667-3683.
53. Fiandalo, M.V. et al. (2012) Caspase control: protagonists of cancer cell apoptosis. Exp. Oncol., 34, 165-175.
54. Reubold, T.F. et al. (2012) A molecular view on signal transduction by the apoptosome. Cell Signal., 24, 1420-1425.
55. Galluzzi, L. et al. (2012) Mitochondria: master regulators of danger signalling. Nat. Rev. Mol. Cell Biol., 13, 780-788.
56. de Almagro, M.C. et al. (2012) The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp. Oncol., 34, 200-211.
57. Harvey, K.F. et al. (2013) The Hippo pathway and human cancer. Nat. Rev. Cancer, 13, 246-257.
58. Sherr, C.J. et al. (2002) The RB and p53 pathways in cancer. Cancer Cell, 2, 103-112.
59. Galluzzi, L. et al. (2011) Mitochondrial liaisons of p53. Antioxid. Redox Signal., 15, 1691-1714.
60. Matoba, S. et al. (2006) p53 regulates mitochondrial respiration. Science, 312, 1650-1653.
61. Kim, J.Y. et al. (2004) BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J. Exp. Med., 199, 113-124.
62. Yu, J. et al. (2008) PUMA, a potent killer with or without p53. Oncogene, 27(suppl 1), S71-S83.
63. Hikisz, P. et al. (2012) PUMA, a critical mediator of cell death-one decade on from its discovery. Cell. Mol. Biol. Lett., 17, 646-669.
64. Icard, P. et al. (2012) A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta, 1826, 423-433.
65. Zhao, S. et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science, 327, 1000-1004.
66. Yi, C.H. et al. (2011) Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell, 146, 607-620.
67. Gnoni, G.V. et al. (2009) The mitochondrial citrate carrier: metabolic role and regulation of its activity and expression. IUBMB Life, 61, 987-994.
68. Vaughn, A.E. et al. (2008) Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell Biol., 10, 1477-1483.
69. Delbridge, A.R. et al. (2012) The role of the apoptotic machinery in tumor suppression. Cold Spring Harb. Perspect. Biol., 4.
70. Labbe, D.P. et al. (2012) Protein tyrosine phosphatases in cancer:friends and foes! Prog. Mol. Biol. Transl. Sci., 106, 253-306.
71. Sayers, T.J. (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol. Immunother., 60, 1173-1180.
72. Frisch, S.M. et al. (1996) A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. J. Cell Biol., 135, 1377-1382.
73. Schottenfeld, D. et al. (2013) Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors. Annu. Rev. Public Health, 34, 97-117.
74. Lee, E.Y. et al. (2010) Oncogenes and tumor suppressor genes. Cold Spring Harb. Perspect. Biol., 2, a003236.
75. Reddy, K.L. et al. (2013) Higher order chromatin organization in cancer. Semin. Cancer Biol., 23, 109-115.
76. Iorio, M.V. et al. (2012) microRNA involvement in human cancer. Carcinogenesis, 33, 1126-1133.
77. Vousden, K.H. et al. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
78. Murray-Zmijewski, F. et al. (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ., 13, 962-972.
79. Rosenbluth, J.M. et al. (2008) The jury is in: p73 is a tumor suppressor after all. Genes Dev., 22, 2591-2595.
80. Flores, E.R. et al. (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, 7, 363-373.
81. Maddocks, O.D. et al. (2011) Metabolic regulation by p53. J. Mol. Med. (Berl), 89, 237-245.
82. Huang, Y. et al. (2011) Phospho-ΔNp63α is a key regulator of the cisplatin- induced microRNAome in cancer cells. Cell Death Differ., 18, 1220-1230.
83. Sen, T. et al. (2011) DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res., 71, 1167-1176.
84. Ory, B. et al. (2011) A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget, 2, 259-264.
85. Xi, S. et al. (2010) Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One, 5, e13764.
86. Ewing, S.J. et al. (2008) C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf). Cell Death Differ., 15, 1734-1744.
87. Balmain, A. et al. (1984) Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature, 307, 658-660.
88. Alguacil, J. et al. (2002) Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis, 23, 101-106.
89. Zarbl, H. et al. (1985) Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature, 315, 382-385.
90. Shishodia, S. et al. (2003) Curcumin (diferuloylmethane) downregulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells:correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis, 24, 1269-1279.
91. Srivastava, S.K. et al. (2004) Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis, 25, 1701-1709.
92. Romano, S. et al. (2011) FKBP51 and the NF-κB regulatory pathway in cancer. Curr. Opin. Pharmacol., 11, 288-293.
93. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
94. Trosko, J.E. et al. (2010) A paradigm shift is required for the risk assessment of potential human health after exposure to low level chemical exposures: a response to the toxicity testing in the 21st century report. Int. J. Toxicol., 29, 344-357.
95. Kleinstreuer, N.C. et al. (2013) In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis. Toxicol. Sci., 131, 40-55.
96. Kortenkamp, A. (2014) Low dose mixture effects of endocrine disrupters and their implications for regulatory thresholds in chemical risk assessment. Curr. Opin. Pharmacol., 19, 105-111.
97. Fucic, A. et al. (2012) Environmental exposure to xenoestrogens and oestrogen related cancers: reproductive system, breast, lung, kidney, pancreas, and brain. Environ. Health, 11(suppl 1), S8.
98. Bailey, S.T. et al. (2012) Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc. Natl Acad. Sci. USA, 109, 18060-18065.
99. Sayeed, A. et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res., 67, 7746-7755.
100. Al-Dhaheri, M. et al. (2011) CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res., 71, 2118-2128.
101. Wik, E. et al. (2013) Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin. Cancer Res., 19, 1094-1105.
102. Dhasarathy, A. et al. (2007) The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol. Endocrinol., 21, 2907-2918.
103. Huet, G. et al. (2008) Loss of E-cadherin-mediated cell contacts reduces estrogen receptor alpha (ER alpha) transcriptional efficiency by affecting the respective contribution exerted by AF1 and AF2 transactivation functions. Biochem. Biophys. Res. Commun., 365, 304-309.
104. Rivedal, E. et al. (2005) Connexin43 synthesis, phosphorylation, and degradation in regulation of transient inhibition of gap junction intercellular communication by the phorbol ester TPA in rat liver epithelial cells. Exp. Cell Res., 302, 143-152.
105. Kang, K.S. et al. (1996) Inhibition of gap junctional intercellular communication in normal human breast epithelial cells after treatment with pesticides, PCBs, and PBBs, alone or in mixtures. Environ. Health Perspect., 104, 192-200.
106. Klaunig, J.E. et al. (1990) Gap-junctional intercellular communication and murine hepatic carcinogenesis. Prog. Clin. Biol. Res., 331, 277-291.
107. Carette, D. et al. (2014) Connexin a check-point component of cell apoptosis in normal and physiopathological conditions. Biochimie, 101, 1-9.
108. Trosko, J.E. et al. (1994) The role of modulated gap junctional intercellular communication in epigenetic toxicology. Risk Anal., 14, 303-312.
109. Chang, W.W. et al. (2013) Salmonella enhance chemosensitivity in tumor through connexin 43 upregulation. Int. J. Cancer, 133, 1926-1935.
110. Abu Aboud, O. et al. (2013) Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One, 8, e71115.
111. Klaunig, J.E. et al. (2003) PPARalpha agonist-induced rodent tumors:modes of action and human relevance. Crit. Rev. Toxicol., 33, 655-780.
112. Roberts, R.A. (2002) Evidence for cross talk between PPARalpha and p38 MAP kinase. Toxicol. Sci., 68, 270-274.
113. Cook, J.C. et al. (1993) Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats. Toxicol. Appl. Pharmacol., 119, 195-204.
114. Zhang, Z. et al. (2011) Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur. J. Obstet. Gynecol. Reprod. Biol., 155, 69-74.
115. Calaf, G.M. et al. (2009) Organophosphorous pesticides and estrogen induce transformation of breast cells affecting p53 and c-Ha-ras genes. Int. J. Oncol., 35, 1061-1068.
116. Petitjean, A. et al. (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 26, 2157-2165.
117. Lu, Y. et al. (2012) Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition. J. Cancer, 3, 333-344.
118. Ruas, M. et al. (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta, 1378, F115-F177.
119. Geisler, S.A. et al. (2002) p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin. Cancer Res., 8, 3445-3453.
120. Jiang, M. et al. (2003) Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev., 17, 832-837.
121. Schwandner, O. et al. (2000) p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur. J. Cancer, 36, 348-356.
122. Miliaras, S. et al. (2011) The role of P53 and Bcl-2 proteins in 7, 12-dimethylbenz-(a)-anthracene-induced tumor growth. J. Biol. Regul. Homeost. Agents, 25, 359-364.
123. Centelles, J.J. (2012) General aspects of colorectal cancer. ISRN Oncol., 2012, 139268.
124. Roskoski, R. Jr. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res., 79, 34-74.
125. Chen, F.L. et al. (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res., 14, 6730-6734.
126. Willems, L. et al. (2012) PI3K and mTOR signaling pathways in cancer:new data on targeted therapies. Curr. Oncol. Rep., 14, 129-138.
127. Laplante, M. et al. (2009) mTOR signaling at a glance. J. Cell Sci., 122(Pt 20), 3589-3594.
128. Graff, J.R. et al. (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res., 68, 631-634.
129. Jia, Y. et al. (2012) Cap-dependent translation initiation factor eIF4E:an emerging anticancer drug target. Med. Res. Rev., 32, 786-814.
130. Blume-Jensen, P. et al. (1998) The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol., 8, 779-782.
131. Downward, J. (2004) PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol., 15, 177-182.
132. Nicholson, K.M. et al. (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal., 14, 381-395.
133. Romashkova, J.A. et al. (1999) NF-kappaB is a target of AKT in antiapoptotic PDGF signalling. Nature, 401, 86-90.
134. Cardone, M.H. et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science, 282, 1318-1321.
135. Maiese, K. et al. (2012) Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin. Ther. Targets, 16, 1203-1214.
136. Tsukada, M. et al. (1993) Isolation and characterization of autophagydefective mutants of Saccharomyces cerevisiae. FEBS Lett., 333, 169-174.
137. Pastor, M.D. et al. (2009) mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J. Biol. Chem., 284, 22067-22078.
138. Tessier, D.M. et al. (2001) Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides. Toxicol. Sci., 60, 38-43.
139. Zhang, W. et al. (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res., 12, 9-18.
140. Lim, J.H. et al. (2012) Rottlerin induces apoptosis of HT29 colon carcinoma cells through NAG-1 upregulation via an ERK and p38 MAPK-dependent and PKC δ-independent mechanism. Chem. Biol. Interact., 197, 1-7.
141. Gan, L. et al. (2011) Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate, 71, 1158-1166.
142. Salim, H. et al. (2012) miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br. J. Cancer, 107, 1361-1373.
143. Hu, C. et al. (2012) E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells. Toxicol. Lett., 210, 78-86.
144. Sui, X. et al. (2014) p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett., 344, 174-179.
145. Dhillon, A.S. et al. (2007) MAP kinase signalling pathways in cancer. Oncogene, 26, 3279-3290.
146. Carmona-Cuenca, I. et al. (2008) Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol., 49, 965-976.
147. Caja, L. et al. (2009) Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res., 69, 7595-7602.
148. Bulayeva, N.N. et al. (2004) Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ. Health Perspect., 112, 1481-1487.
149. Andersen, M. et al. (1978) Mutagenic action of aromatic epoxy resins. Nature, 276, 391-392.
150. Ashby, J. et al. (1988) Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. Mutat. Res., 204, 17-115.
151. Masuda, S. et al. (2005) Changes in the mutagenic and estrogenic activities of bisphenol A upon treatment with nitrite. Mutat. Res., 585, 137-146.
152. Dairkee, S.H. et al. (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis, 34, 703-712.
153. Goodson, W.H. III et al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis, 32, 1724-1733.
154. Pupo, M. et al. (2012) Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer- associated fibroblasts. Environ. Health Perspect., 120, 1177-1182.
155. Allard, P. et al. (2010) Bisphenol A impairs the double-strand break repair machinery in the germline and causes chromosome abnormalities. Proc. Natl Acad. Sci. USA, 107, 20405-20410.
156. Jenkins, S. et al. (2011) Chronic oral exposure to bisphenol A results in a nonmonotonic dose response in mammary carcinogenesis and metastasis in MMTV-erbB2 mice. Environ. Health Perspect., 119, 1604-1609.
157. Mozzachio, A.M. et al. (2008) Chlorothalonil exposure and cancer incidence among pesticide applicator participants in the agricultural health study. Environ. Res., 108, 400-403.
158. Wilkinson, C.F. et al. (1996) A mechanistic interpretation of the oncogenicity of chlorothalonil in rodents and an assessment of human relevance. Regul. Toxicol. Pharmacol., 24(1 Pt 1), 69-84.
159. Leung-Toung, R. et al. (2006) Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem., 13, 547-581.
160. Rakitsky, V.N. et al. (2000) Nongenotoxic (epigenetic) carcinogens:pesticides as an example. A critical review. Teratog. Carcinog. Mutagen., 20, 229-240.
161. Swan, S.H. (2008) Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. Environ. Res., 108, 177-184.
162. Kim, I.Y. et al. (2004) Phthalates inhibit tamoxifen-induced apoptosis in MCF-7 human breast cancer cells. J. Toxicol. Environ. Health. A, 67, 2025-2035.
163. Liu, X. et al. (2009) Di-(2-ethylhexyl) phthalate upregulates ATF3 expression and suppresses apoptosis in mouse genital tubercle. J. Occup. Health, 51, 57-63.
164. Maire, M.A. et al. (2005) Di-(2-ethylhexyl)phthalate (DEHP) increases Bcl-2/Bax ratio and modifies c-myc expression in Syrian hamster embryo (SHE) cells. Toxicol. Lett., 158, 237-245.
165. Hsieh, T.H. et al. (2012) Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. FASEB J., 26, 778-787.
166. Park, M.A. et al. (2012) Cell growth of BG-1 ovarian cancer cells is promoted by di-n-butyl phthalate and hexabromocyclododecane via upregulation of the cyclin D and cyclin-dependent kinase-4 genes. Mol. Med. Rep., 5, 761-766.
167. Rusyn, I. et al. (2006) Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit. Rev. Toxicol., 36, 459-479.
168. Isenberg, J.S. et al. (2001) Reversibility and persistence of di-2-ethylhexyl phthalate (DEHP)- and phenobarbital-induced hepatocellular changes in rodents. Toxicol. Sci., 64, 192-199.
169. Erkekoğlu, P. et al. (2011) Induction of ROS, p53, p21 in DEHP- and MEHP-exposed LNCaP cells-protection by selenium compounds. Food Chem. Toxicol., 49, 1565-1571.
170. Reuber, M.D. (1981) Carcinogenicity of dichlorvos. Clin. Toxicol., 18, 47-84.
171. Koutros, S. et al. (2008) Dichlorvos exposure and human cancer risk:results from the Agricultural Health Study. Cancer Causes Control, 19, 59-65.
172. Page, A.C. et al. (1972) Metabolic fate of dichlorvos in swine. Arch. Toxikol., 30, 19-27.
173. Chan, P.C. et al. (1991) Carcinogenesis studies of dichlorvos in Fischer rats and B6C3F1 mice. Jpn. J. Cancer Res., 82, 157-164.
174. Eroğlu, S. et al. (2013) Protective role of vitamins C and E in dichlorvos- induced oxidative stress in human erythrocytes in vitro. Biol. Res., 46, 33-38.
175. Sunkaria, A. et al. (2013) Dichlorvos-induced cell cycle arrest and DNA damage repair activation in primary rat microglial cells. J. Neurosci. Res., 91, 444-452.
176. Hervouet, E. et al. (2013) DNA methylation and apoptosis resistance in cancer cells. Cells, 2, 545-573.
177. Alavanja, M.C. et al. (2005) Pesticides and human cancers. Cancer Invest., 23, 700-711.
178. Li, Q. et al. (2007) Organophosphorus pesticides induce apoptosis in human NK cells. Toxicology, 239, 89-95.
179. Bhatt, D.K. et al. (2009) Modulation of tricarboxylic acid cycle dehydrogenases during hepatocarcinogenesis induced by hexachlorocyclohexane in mice. Exp. Toxicol. Pathol., 61, 325-332.
180. Bhatt, D.K. et al. (2012) Modulation of acid phosphatase and lactic dehydrogenase in hexachlorocyclohexane-induced hepatocarcinogenesis in mice. J. Biochem. Mol. Toxicol., 26, 439-444.
181. Zucchini-Pascal, N. et al. (2009) Lindane and cell death: at the crossroads between apoptosis, necrosis and autophagy. Toxicology, 256, 32-41.
182. Zucchini-Pascal, N. et al. (2011) Molecular investigation of the effects of lindane in rat hepatocytes: microarray and mechanistic studies. Food Chem. Toxicol., 49, 3128-3135.
183. Roloff, B.D. et al. (1992) Cytogenetic studies of herbicide interactions in vitro and in vivo using atrazine and linuron. Arch. Environ. Contam. Toxicol., 22, 267-271.
184. Gao, X. et al. (2000) Effects of polychlorinated dibenzofurans, biphenyls, and their mixture with dibenzo-p-dioxins on ovulation in the gonadotropin-primed immature rat: support for the toxic equivalency concept. Toxicol. Appl. Pharmacol., 163, 115-124.
185. Kim, J.Y. et al. (2014) Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway. Environ. Toxicol. Pharmacol., 37, 1264-1274.
186. Gupta, R.K. et al. (2006) Methoxychlor causes mitochondrial dysfunction and oxidative damage in the mouse ovary. Toxicol. Appl. Pharmacol., 216, 436-445.
187. Eroschenko, V.P. et al. (1996) Estradiol or methoxychlor stimulates estrogen receptor (ER) expression in uteri. Reprod. Toxicol., 10, 265-271.
188. Gray, L.E. et al. (2001) Effects of environmental antiandrogens on reproductive development in experimental animals. Hum. Reprod. Update, 7, 248-264.
189. Kretschmer, X.C. et al. (2005) CAR and PXR: xenosensors of endocrine disrupters? Chem. Biol. Interact., 155, 111-128.
190. di Masi, A. et al. (2009) Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol. Aspects Med., 30, 297-343.
191. Huang, P. et al. (2003) Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. Eur. J. Clin. Pharmacol., 59, 471-476.
192. Stagg, N.J. et al. (2012) Assessment of possible carcinogenicity of oxyfluorfen to humans using mode of action analysis of rodent liver effects. Toxicol. Sci., 128, 334-345.
193. Reddy, J.K. et al. (1980) Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature, 283, 397-398.
194. Corton, J. (2010) Cancer risk assessment: chemical carcinogenesis, hazard evaluation, and risk quantification. In Hsu, C.H. and Stedeford, T. (eds). John Wiley & Sons, Hoboken, NJ, pp. 439-467.
195. Qu, A. et al. (2010) PPARalpha-dependent activation of cell cycle control and DNA repair genes in hepatic nonparenchymal cells. Toxicol. Sci., 118, 404-410.
196. Guenther, M.K. et al. (2013) Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett., 337, 200-209.
197. Daniel, M. et al. (2012) Regulation of the human catalytic subunit of telomerase (hTERT). Gene, 498, 135-146.
198. Kyo, S. et al. (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci., 99, 1528-1538.
199. Clere, N. et al. (2012) Estrogen receptor alpha as a key target of organochlorines to promote angiogenesis. Angiogenesis, 15, 745-760.
200. Silva, E. et al. (2010) Cross-talk between non-genomic and genomic signalling pathways-distinct effect profiles of environmental estrogens. Toxicol. Appl. Pharmacol., 245, 160-170.
201. Lee, H.R. et al. (2012) Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway. Int. J. Mol. Med., 29, 883-890.
202. Park, S.H. et al. (2008) Estrogen regulates Snail and Slug in the downregulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol. Endocrinol., 22, 2085-2098.
203. Giretti, M.S. et al. (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One, 3, e2238.
204. Eritja, N. et al. (2012) ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFα and IL1α in lumen formation and maintenance. J. Cell Sci., 125(Pt 8), 1929-1944.
205. Soreq, H. (1985) The biosynthesis of biologically active proteins in mRNA-microinjected Xenopus oocytes. CRC Crit. Rev. Biochem., 18, 199-238.
206. Grubisha, M.J. et al. (2013) Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment. Steroids, 78, 538-541.
207. Kim, H.R. et al. (2013) p53 regulates glucose metabolism by miR-34a. Biochem. Biophys. Res. Commun., 437, 225-231.
208. Vousden, K.H. et al. (2009) Blinded by the light: the growing complexity of p53. Cell, 137, 413-431.
209. Teodoro, J.G. et al. (2006) p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science, 313, 968-971.
210. Hanel, W. et al. (2012) Links between mutant p53 and genomic instability. J. Cell. Biochem., 113, 433-439.
211. Harris, C.C. et al. (1993) Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329, 1318-1327.
212. Niebler, M. et al. (2013) Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog., 9, e1003536.
213. Gildener-Leapman, N. et al. (2013) Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol., 49, 1089-1096.
214. Sperka, T. et al. (2012) DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol., 13, 579-590.
215. Qian, Y. et al. (2013) Senescence regulation by the p53 protein family. Methods Mol. Biol., 965, 37-61.
216. Lu, W. et al. (2013) Telomeres-structure, function, and regulation. Exp. Cell Res., 319, 133-141.
217. Artandi, S.E. et al. (2010) Telomeres and telomerase in cancer. Carcinogenesis, 31, 9-18.
218. Lee, J.S. et al. (2014) A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro. Oncol., 16, 191-203.
219. Muller, P.A. et al. (2011) p53 and its mutants in tumor cell migration and invasion. J. Cell Biol., 192, 209-218.
220. Goh, A.M. et al. (2011) The role of mutant p53 in human cancer. J. Pathol., 223, 116-126.
221. Roger, L. et al. (2006) Control of cell migration: a tumour suppressor function for p53? Biol. Cell, 98, 141-152.
222. Goh, H.S. et al. (1999) p53 point mutation and survival in colorectal cancer patients: effect of disease dissemination and tumour location. Int. J. Oncol., 15, 491-498.
223. Luo, M. et al. (2013) Two-stage model of chemically induced hepatocellular carcinoma in mouse. Oncol. Res., 20, 517-528.
224. Cooks, T. et al. (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell, 23, 634-646.
225. Hussain, S.P. et al. (2007) Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer, 121, 2373-2380.
226. Lorin, S. et al. (2013) Autophagy regulation and its role in cancer. Semin. Cancer Biol., 23, 361-379.
227. Tsai, C.M. et al. (1996) Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res., 56, 206-209.
228. Arriola, E. et al. (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab. Invest., 88, 491-503.
229. Biroccio, A. et al. (2004) Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocr. Relat. Cancer, 11, 407-421.
230. Vageli, D. et al. (2009) Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway. Oncol. Res., 17, 413-423.
231. Fuchs, I.B. et al. (2002) The prognostic significance of epithelialmesenchymal transition in breast cancer. Anticancer Res., 22(6A), 3415-3419.
232. Ortega-Cava, C.F. et al. (2011) Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. J. Carcinog., 10, 29.
233. Xi, C. et al. (2012) Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis. J. Biol. Chem., 287, 35646-35657.
234. Moreira Sousa, C. et al. (2013) The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol. Med., 5, 309-325.
235. Yuan, H. et al. (2013) PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation. Cancer Res., 73, 4349-4361.
236. Mohammed, Z.M. et al. (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br. J. Cancer, 107, 864-873.
237. Olson, O.C. et al. (2013) Microenvironment-mediated resistance to anticancer therapies. Cell Res., 23, 179-181.
238. Min, J.W. et al. (2013) INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem. Biophys. Res. Commun., 440, 137-142.
239. Kim, J.G. et al. (2013) Association between phosphorylated AMPactivated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Oncology, 85, 78-85.
240. Agarwal, M.L. et al. (2001) Regulation of p53 expression by the RASMAP kinase pathway. Oncogene, 20, 2527-2536.
241. Wu, G.S. (2004) The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol. Ther., 3, 156-161.
242. Murphy, D.A. et al. (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am. J. Pathol., 169, 1875-1885.
243. Corcelle, E. et al. (2006) Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. Cancer Res., 66, 6861-6870.
244. Lin, Y.W. et al. (2003) Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anticytotoxicity and anti-mutagenicity. Carcinogenesis, 24, 53-61.
245. Wang, S. et al. (2006) Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood, 107, 2432-2439.
246. Duan, S.G. et al. (2010) The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells. Dig. Dis. Sci., 55, 2844-2852.
247. Bermudez, Y. et al. (2008) Pyk2/ERK 1/2 mediate Sp1- and c-Mycdependent induction of telomerase activity by epidermal growth factor. Growth Factors, 26, 1-11.
248. Krueger, J.S. et al. (2001) Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene, 20, 4209-4218.
249. Davies, M. et al. (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGFbeta1 involves MAPK, Smad and AP-1 signalling pathways. J. Cell. Biochem., 95, 918-931.
250. Reddy, K.B. et al. (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev., 22, 395-403.
251. Weng, C.J. et al. (2008) Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1. Carcinogenesis, 29, 147-156.
252. Wegiel, B. et al. (2009) Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One, 4, e7953.
253. Wang, L.N. et al. (2011) Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord. Mol. Pain, 7, 48.
254. Zhang, Y. et al. (2013) Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res., 73, 6359-6374.
255. Weinberg, F. et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA, 107, 8788-8793.
256. Lee, S.W. et al. (2000) Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc. Natl Acad. Sci. USA, 97, 8302-8305.
257. Berra, E. et al. (2000) Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol., 60, 1171-1178.
258. Saavedra, H.I. et al. (2000) The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene, 19, 3948-3954.
259. Gong, W. et al. (2011) Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway. J. Chemother., 23, 295-299.
260. Inui, T. et al. (2001) Telomerase activation and MAPK pathways in regenerating hepatocytes. Hum. Cell, 14, 275-282.
261. Matsuo, T. et al. (2012) Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas. J. Exp. Clin. Cancer Res., 31, 5.
262. Ge, Z. et al. (2006) Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation. Mol. Cell. Biol., 26, 230-237.
263. Olejarz, W. et al. (2014) Mycophenolic acid attenuates the tumour necrosis factor-α-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-κB and ROS pathways. Eur. J. Clin. Invest., 44, 54-64.
264. Ji, R.R. et al. (2009) MAP kinase and pain. Brain Res. Rev., 60, 135-148.
265. Li, L. et al. (2010) Inhibition of hypoxia-induced cell motility by p16 in MDA-MB-231 breast cancer cells. J. Cancer, 1, 126-135.
266. McDermott, K.M. et al. (2006) p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol., 4, e51.
267. Wang, P. et al. (2013) Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma. J. Chin. Med. Assoc., 76, 135-139.
268. Montes, C.L. et al. (2008) Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res., 68, 870-879.
269. Stoll, E.A. et al. (2013) The impact of age on oncogenic potential:tumor-initiating cells and the brain microenvironment. Aging Cell, 12, 733-741.
270. Rayess, H. et al. (2012) Cellular senescence and tumor suppressor gene p16. Int. J. Cancer, 130, 1715-1725.
271. Iannone, F. et al. (2005) Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism. Ann. Rheum. Dis., 64, 217-221.
272. Kawabuchi, B. et al. (1999) p16 inactivation in small-sized lung adenocarcinoma:its association with poor prognosis. Int. J. Cancer, 84, 49-53.
273. Hui, A.M. et al. (2000) Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Lett., 154, 93-99.
274. Tada, T. et al. (2003) Reduced p16 expression correlates with lymphatic invasion in colorectal cancers. Hepatogastroenterology, 50, 1756-1760.
275. Wang, C.H. et al. (2006) p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J. Cell. Physiol., 208, 246-252.
276. Achyut, B.R. et al. (2013) Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet., 9, e1003251.
277. Amelio, I. et al. (2011) Cell death pathology: cross-talk with autophagy and its clinical implications. Biochem. Biophys. Res. Commun., 414, 277-281.
278. Decary, S. et al. (2002) The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its transcription in epithelial cells through transcription factor AP-2. Mol. Cell. Biol., 22, 7877-7888.
279. Huang, H. et al. (2004) Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene, 23, 2161-2176.
280. Crescenzi, E. et al. (2001) Bcl-2 exerts a pRb-mediated cell cycle inhibitory function in HEC1B endometrial carcinoma cells. Gynecol. Oncol., 81, 184-192.
281. Ha, J.H. et al. (2013) Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. J. Biol. Chem., 288, 7387-7398.
282. Staibano, S. et al. (2001) Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck. Anticancer Res., 21(6A), 3757-3764.
283. Esposito, F. et al. (2012) High-mobility group A1 protein inhibits p53-mediated intrinsic apoptosis by interacting with Bcl-2 at mitochondria. Cell Death Dis., 3, e383.
284. Bharatham, N. et al. (2011) Molecular basis of Bcl-X(L)-p53 interaction:insights from molecular dynamics simulations. PLoS One, 6, e26014.
285. Basu, A. et al. (1998) The relationship between BcI2, Bax and p53:consequences for cell cycle progression and cell death. Mol. Hum. Reprod., 4, 1099-1109.
286. Dogu, Y. et al. (2009) Mathematical model of a network of interaction between p53 and Bcl-2 during genotoxic-induced apoptosis. Biophys. Chem., 143, 44-54.
287. Tomita, Y. et al. (2006) WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem., 281, 8600-8606.
288. Biroccio, A. et al. (2000) Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J., 14, 652-660.
289. Zuo, J. et al. (2010) Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis. Mol. Cancer Res., 8, 170-182.
290. Nelson, D.A. et al. (2004) Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev., 18, 2095-2107.
291. Zheng, J.M. et al. (2005) [bcl-2 expression in small cell lung cancer: a mechanism for apoptosis antagonism and immune evasion]. Di Yi Jun Yi Da Xue Xue Bao, 25, 1537-1539.
292. Huerta, S. et al. (2007) Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J. Surg. Res., 142, 184-194.
293. Zuo, J. et al. (2011) Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathog., 7, e1002455.
294. Mandal, M. et al. (1997) Bcl-2 modulates telomerase activity. J. Biol. Chem., 272, 14183-14187.
295. Wang, X. et al. (2007) Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol., 9, 470-478.
296. Sun, T. et al. (2011) Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology, 54, 1690-1706.
297. Chung, G.T. et al. (2013) Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. J. Pathol., 231, 311-322.
298. Singh, V. et al. (2009) A tumour stage-dependent evolution of drug resistant T cell lymphoma: role of soluble mediators of tumour and host origin. Leuk. Res., 33, 700-709.
299. Wang, B. et al. (2012) Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology, 56, 186-197.
300. Kloetzel, M. et al. (2013) Trans fatty acids affect cellular viability of human intestinal Caco-2 cells and activate peroxisome proliferatoractivated receptors. Nutr. Cancer, 65, 139-146.
301. Gizard, F. et al. (2008) The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycledependent telomerase activation. Circ. Res., 103, 1155-1163.
302. Gizard, F. et al. (2005) PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J. Clin. Invest., 115, 3228-3238.
303. Gopinathan, L. et al. (2009) Regulation of peroxisome proliferatoractivated receptor-alpha by MDM2. Toxicol. Sci., 108, 48-58.
304. Pozzi, A. et al. (2008) PPARalpha ligands as antitumorigenic and antiangiogenic Agents. PPAR Res., 2008, 906542.
305. Moraes, L.A. et al. (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther., 110, 371-385.
306. Tang, C.C. et al. (2013) Hepatoprotective effect of mulberry water extracts on ethanol-induced liver injury via anti-inflammation and inhibition of lipogenesis in C57BL/6J mice. Food Chem. Toxicol., 62, 786-796.
307. Goldring, M.B. et al. (2004) The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin. Orthop. Relat. Res., S37-S46.
308. Spath, C. et al. (2013) Inverse relationship between tumor proliferation markers and connexin expression in a malignant cardiac tumor originating from mesenchymal stem cell engineered tissue in a Rat in vivo model. Front. Pharmacol., 4, 42.
309. Yano, T. et al. (2006) Connexin 32 as an anti-invasive and antimetastatic gene in renal cell carcinoma. Biol. Pharm. Bull., 29, 1991-1994.
310. Li, Q. et al. (2007) Cytoplasmic accumulation of connexin32 protein enhances motility and metastatic ability of human hepatoma cells in vitro and in vivo. Int. J. Cancer, 121, 536-546.
311. Sato, H. et al. (2007) Regulation of renal cell carcinoma cell proliferation, invasion and metastasis by connexin 32 gene. J. Membr. Biol., 216, 17-21.
312. Trosko, J.E. et al. (2006) Adult stem cell theory of the multi-stage, multi-mechanism theory of carcinogenesis: role of inflammation on the promotion of initiated stem cells. Contrib. Microbiol., 13, 45-65.
313. Corn, P.G. (2012) The tumor microenvironment in prostate cancer:elucidating molecular pathways for therapy development. Cancer Manag. Res., 4, 183-193.
314. Cui, J. et al. (2011) MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS One, 6, e21730.
315. Choi, J.H. et al. (2006) Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res., 66, 3912-3920.
316. Lau, M.T. et al. (2010) Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology, 151, 2985-2993.
317. Herman, A.P. et al. (2013) LPS-induced inflammation potentiates the IL-1β-mediated reduction of LH secretion from the anterior pituitary explants. Clin. Dev. Immunol., 2013, 926937.
318. Sand, E. et al. (2013) Gonadotropin-releasing hormone analog buserelin causes neuronal loss in rat gastrointestinal tract. Cell Tissue Res., 351, 521-534.
319. Fillon, M. (2012) Getting it right: BPA and the difficulty proving environmental cancer risks. J. Natl Cancer Inst., 104, 652-655.
320. Jiang, Y. et al. (2014) Prenatal exposure to bisphenol A at the reference dose impairs mitochondria in the heart of neonatal rats. J. Appl. Toxicol., 34, 1012-1022.
321. Lee, H.S. et al. (2012) Set, a putative oncogene, as a biomarker for prenatal exposure to bisphenol A. Asian Pac. J. Cancer Prev., 13, 2711-2715.
322. Betancourt, A.M. et al. (2012) Altered carcinogenesis and proteome in mammary glands of rats after prepubertal exposures to the hormonally active chemicals bisphenol a and genistein. J. Nutr., 142, 1382S-1388S.
323. Durando, M. et al. (2011) Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J. Steroid Biochem. Mol. Biol., 127, 35-43.
324. Goloubkova, T. et al. (2000) Effects of xenoestrogen bisphenol A on uterine and pituitary weight, serum prolactin levels and immunoreactive prolactin cells in ovariectomized Wistar rats. Arch. Toxicol., 74, 92-98.
325. Kurosawa, T. et al. (2002) The activity of bisphenol A depends on both the estrogen receptor subtype and the cell type. Endocr. J., 49, 465-471.
326. Zhu, H. et al. (2010) Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Oncol. Rep., 23, 129-139.
327. Derouiche, S. et al. (2013) Bisphenol A stimulates human prostate cancer cell migration via remodelling of calcium signalling. Springerplus, 2, 54.
328. Tenev, T. et al. (2011) The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell, 43, 432-448.
329. Hassan, Z.K. et al. (2012) Bisphenol A induces hepatotoxicity through oxidative stress in rat model. Oxid. Med. Cell. Longev., 2012, 194829.
330. Kleinsasser, N.H. et al. (2000) Phthalates demonstrate genotoxicity on human mucosa of the upper aerodigestive tract. Environ. Mol. Mutagen., 35, 9-12.
331. Li, X. et al. (2014) Dibutyl phthalate-induced neurotoxicity in the brain of immature and mature rat offspring. Brain Dev., 36, 653-660.
332. Pariseau, J. et al. (2011) Effects of pesticide compounds (chlorothalonil and mancozeb) and benzo[a]pyrene mixture on aryl hydrocarbon receptor, p53 and ubiquitin gene expression levels in haemocytes of soft-shell clams (Mya arenaria). Ecotoxicology, 20, 1765-1772.
333. Lebailly, P. et al. (1997) Assessment of DNA damage induced in vitro by etoposide and two fungicides (carbendazim and chlorothalonil) in human lymphocytes with the comet assay. Mutat. Res., 375, 205-217.
334. Nagda, G. et al. (2011) Alleviation of lindane induced toxicity in testis of Swiss mice (Mus musculus) by combined treatment with vitamin C, vitamin E and alpha-lipoic acid. Indian J. Exp. Biol., 49, 191-199.
335. Bharathi, S.P. et al. (2013) Role of pesticides in the induction of tumor angiogenesis. Anticancer Res., 33, 231-240.
336. Bhunya, S.P. et al. (1992) Genotoxic potential of the organochlorine insecticide lindane (gamma-BHC): an in vivo study in chicks. Mutat. Res., 272, 175-181.
337. Isoda, H. et al. (2005) Effects of organophosphorous pesticides used in china on various mammalian cells. Environ. Sci., 12, 9-19.
338. Nilufer Yonguc, G. et al. (2012) Caspase 1, caspase 3, TNF-alpha, p53, and Hif1-alpha gene expression status of the brain tissues and hippocampal neuron loss in short-term dichlorvos exposed rats. Mol. Biol. Rep., 39, 10355-10360.
339. Wang, Q.L. et al. (2013) Risk assessment of mouse gastric tissue cancer induced by dichlorvos and dimethoate. Oncol. Lett., 5, 1385-1389.
340. Rishi, K.K. et al. (1995) Chromosome aberration test for the insecticide, dichlorvos, on fish chromosomes. Mutat. Res., 344, 1-4.
341. Sunkaria, A. et al. (2012) Dichlorvos exposure results in activation induced apoptotic cell death in primary rat microglia. Chem. Res. Toxicol., 25, 1762-1770.
342. Laws, S.C. et al. (2000) Estrogenic activity of octylphenol, nonylphenol, bisphenol A and methoxychlor in rats. Toxicol. Sci., 54, 154-167.
343. Hodgson, A.V. et al. (1998) Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis, 19, 2169-2172.
344. Nishino, R. et al. (2013) Prior oral exposure to environmental immunosuppressive chemicals methoxychlor, parathion, or piperonyl butoxide aggravates allergic airway inflammation in NC/Nga mice. Toxicology, 309, 1-8.
345. Fukuyama, T. et al. (2012) Role of regulatory T cells in the induction of atopic dermatitis by immunosuppressive chemicals. Toxicol. Lett., 213, 392-401.
346. Rao, K.N. et al. (1997) Hepatic hyperplasia and cancer in rats: metabolic alterations associated with cell growth. Gastroenterology, 113, 238-248.
347. Moushumi Priya, A. et al. (2012) Induction of apoptosis and cell cycle arrest by Bis (2-ethylhexyl) phthalate produced by marine Bacillus pumilus MB 40. Chem. Biol. Interact., 195, 133-143.
348. Pasquini, R. et al. (1994) Assay of linuron and a pesticide mixture commonly found in the Italian diet, for promoting activity in rat liver carcinogenesis. Pharmacol. Toxicol., 75, 170-176.
349. Mazzoleni, G. et al. (1994) Influence of the herbicide Linuron on growth rate and gap-junctional intercellular communication of cultured endothelial cells. J. Environ. Pathol. Toxicol. Oncol., 13, 1-10.
350. Barshteĭn, I.u.A. et al. (1990) [An immunological and morphological study of focal staphylococcal infection against a background of longterm exposure to the herbicide linuron]. Mikrobiol. Zh., 52, 52-59.
351. Dairkee, S.H. et al. (2008) Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res., 68, 2076-2080.
352. Lee, I.K. et al. (2007) Inhibitory effect of bisphenol A on gap junctional intercellular communication in an epithelial cell line of rat mammary tissue. Arch. Pharm. Res., 30, 337-343.
353. Weng, Y.I. et al. (2010) Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol. Appl. Pharmacol., 248, 111-121.